| ₹ crore | Q2 FY27 | Q2 FY26 | Change |
|---|---|---|---|
| Revenue | 1,122 | 804 | +39.6% |
| EBITDA | 186 | 141 | +32.1% |
| EBITDA margin | 16.6% | 17.5% | −0.9 pts |
| Profit before tax | 147 | 133 | +10.7% |
| Net profit | 112 | 102 | +10.0% |
| EPS | ₹4.67 | ₹4.26 | +9.6% |
Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.
| Tap a line for its trend | Currentlast 12M | FY26Mar 2026 | FY25Mar 2025 | FY24Mar 2024 |
|---|
| 14,405 | — | — | — | |
| 1,161 | 1,400 | 1,531 | 985 | |
| 0.0 | 0.0 | 0.0 | 403 | |
| 13,244 | — | — | — | |
| 4,131 | 3,511 | 2,839 | 2,590 | |
| — | +23.6% | +9.6% | — | |
| 683 | 619 | 534 | 505 | |
| 16.5% | 17.6% | 18.8% | 19.5% | |
| 511 | 493 | 454 | 429 | |
| 411 | 401 | 407 | 337 | |
| 10.0% | 11.4% | 14.3% | 13.0% | |
| ₹17.09 | ₹16.68 | ₹16.91 | ₹14.33 | |
| — | −1.4% | +18.0% | — | |
| — | 651 | 442 | 508 | |
| — | −44.3 | −30.0 | −10.7 | |
| 607 | 607 | 412 | 497 | |
From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.
In ₹ Crore except Per Share 12 Months Ending | FY24 31/03/2024 | FY25 31/03/2025 | FY26 31/03/2026 | Current/LTM TTM · last close | |
|---|---|---|---|---|---|
| Market Capitalization | — | — | — | 14,404.7 | |
| - Cash, Equiv & ST Investments | 985.1 | 1,530.7 | 1,400.3 | 1,160.5 | |
| + Total Debt | 403.1 | 0.0 | 0.0 | 0.0 | |
| Enterprise Value | — | — | — | 13,244.2 | |
| Revenue | 2,589.6 | 2,839.3 | 3,510.5 | 4,130.9 | |
| Growth %, YoY | — | +9.6 | +23.6 | — | |
| EBITDA | 505.4 | 534.3 | 619.0 | 683.0 | |
| Margin % | 19.52 | 18.82 | 17.63 | 16.53 | |
| EBIT | 429.3 | 454.1 | 492.6 | 511.1 | |
| Net Income | 336.7 | 406.7 | 401.1 | 411.1 | |
| Margin % | 13.00 | 14.32 | 11.43 | 9.95 | |
| EPS, Adj (current shares) | 14.33 | 16.91 | 16.68 | 17.09 | |
| Growth %, YoY | — | +18.0 | -1.4 | — | |
| Cash from Operations | 507.7 | 441.9 | 650.8 | — | |
| Capital Expenditures | -10.7 | -30.0 | -44.3 | — | |
| Free Cash Flow | 497.0 | 411.9 | 606.5 | 606.5 | |
Prices at the 29 October 2026 close · figures from the company's filings with NSE
Indegene (NSE: INDGN) had a market capitalisation of ₹14,272 crore at the 29 October 2026 close (₹593.45 a share), a PE ratio of 34.7 on the last four quarters' profit and a price-to-book ratio of 4.25. In FY26 its consolidated net profit was ₹401 crore on revenue of ₹3,511 crore; in Q2 FY27 (July–September 2026) it was ₹112 crore, up 10.0% year on year. It had no borrowings on 30 September 2026.
Indegene's PE ratio is 34.7 at the 29 October 2026 close (₹593.45 a share): a market capitalisation of ₹14,272 crore divided by consolidated net profit of ₹411 crore over the last four quarters (Q3 FY26 to Q2 FY27). On FY26 net profit (₹401 crore) it is 35.6.
Indegene's net worth — shareholders' equity in its consolidated balance sheet — was ₹3,358 crore on 30 September 2026, up 17.2% from ₹2,866 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹14,272 crore at the 29 October 2026 close.
Indegene's book value per share was ₹139.64 on 30 September 2026: shareholders' equity of ₹3,358 crore divided by the 24.05 crore shares in issue, up 17.0% from ₹119.40 a year earlier. The share price at the 29 October 2026 close was ₹593.45.
Indegene's price-to-book (PB) ratio is 4.25 at the 29 October 2026 close: a market capitalisation of ₹14,272 crore divided by shareholders' equity (book value) of ₹3,358 crore on 30 September 2026. That is a book value of ₹139.64 per share against a share price of ₹593.45.
In FY26, Indegene's return on equity (ROE) was 13.9% and its return on capital employed (ROCE) was 15.7%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 20.1% and ROCE 19.3%.
Indegene's dividend yield is 0.38% at the 29 October 2026 close: dividends of ₹2.25 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹593.45. They were ₹2.25 on 31 July 2026.
Indegene's market capitalisation was ₹14,272 crore at the 29 October 2026 close: 24.05 crore shares at ₹593.45 each.
Yes. Indegene had no borrowings on 30 September 2026 (consolidated balance sheet), and it held ₹1,256 crore of cash, bank balances and current investments.
Indegene's debt-to-equity ratio was 0.00 on 30 September 2026: no borrowings against total equity of ₹3,358 crore. A year earlier, on 30 September 2025, it was 0.00.
Indegene's basic earnings per share (EPS) were ₹16.72 in FY26, against ₹17.15 in FY25. Over the last four quarters (Q3 FY26 to Q2 FY27) they add up to ₹17.12.
In 2026, Indegene has declared one dividend: ₹2.25 with record date 31 July 2026.
Indegene has no promoter group: on 30 September 2026 promoters held 0% of its shares, according to the shareholding pattern filed with NSE. Foreign portfolio investors held 12.40% and domestic institutions 15.82%.
On 30 September 2026, Indegene's shares were held by foreign portfolio investors (FII/FPI) 12.40%, domestic institutions (DII) 15.82% (including mutual funds at 12.25%) and retail and other non-institutional investors 71.77%. Over the year, FII holding was up 1.10 percentage points from 11.30% and DII holding was up 8.86 percentage points from 6.96%.
Indegene's latest results are for Q2 FY27 (July–September 2026), filed on 29 October 2026: consolidated net profit ₹112 crore, up 10.0% from ₹102 crore in Q2 FY26; revenue from operations ₹1,122 crore, up 39.6% year on year.
At the 29 October 2026 closing prices, on FY26 net profit, Indegene's PE ratio is 35.6, the second highest of the four: Syngene International 50.8, LTTS 34.7 and Granules India 34.9, a peer average of 40.1. Each is the company's market capitalisation at that price divided by its FY26 net profit.
In FY26, Indegene generated ₹651 crore of cash from operations and spent ₹44.3 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹607 crore. In FY25 it was ₹412 crore.
In FY26 (April 2025–March 2026), Indegene's consolidated net profit was ₹401 crore, down 1.4% from ₹407 crore in FY25, on revenue from operations of ₹3,511 crore (up 23.6%).
Indegene has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.
On FY26 consolidated figures, against Syngene International, LTTS and Granules India: Indegene's operating margin of 14.0% is the third highest of the four (Syngene International 12.5%, LTTS 14.5%, Granules India 16.6%; peer average 14.5%); its return on equity of 13.9% is the second highest of the four (Syngene International 6.6%, LTTS 20.4%, Granules India 13.5%; peer average 13.5%).
In FY26, Indegene earned net profit of ₹401 crore on revenue of ₹3,511 crore, against ₹317 crore on ₹3,739 crore for Syngene International. Indegene's operating margin was 14.0% (Syngene International 12.5%) and its return on equity 13.9% (Syngene International 6.6%). At the 29 October 2026 close, Indegene's market capitalisation was ₹14,272 crore against ₹16,091 crore for Syngene International, and its PE ratio on FY26 profit 35.6 against 50.8.
From Indegene's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.